Conduit Pharmaceuticals (FRA:ZK70) Total Assets : €2.70 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Total Assets?

Conduit Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was €2.70 Mil.

During the past 12 months, Conduit Pharmaceuticals's average Total Assets Growth Rate was -15.80% per year.

Total Assets is connected with ROA %. Conduit Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 was -807.49%. Total Assets is also linked to Revenue through Asset Turnover. Conduit Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Conduit Pharmaceuticals Total Assets Historical Data

The historical data trend for Conduit Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Total Assets Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Total Assets

0.01

6.62

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial						11.26	6.62	4.52	3.07	2.70

Conduit Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Conduit Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-0.419	+	7.043
	=	6.62

Conduit Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-8.215	+	10.912
	=	2.70

Conduit Pharmaceuticals (FRA:ZK70) Total Assets Explanation

Total Assets is connected with ROA %.

Conduit Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-23.284	/	( (3.07	+	2.697)	/ 2 )
	=	-23.284	/	2.8835
	=	-807.49 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Conduit Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (3.07	+	2.697)	/ 2 )
=	0	/	2.8835
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Conduit Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CDT:USA

Address

4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines